Sharmila Jandial

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial”.

Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial

Trials(2020)10.1186/s13063-020-04796-z

N/A

0.956DataRank · unranked

24 citations

Caleb D. Ebert, Nicole K. Kelly, Travis C. Porco, Athimalaipet V Ramanan, Benjamin F. Arnold +37 more

Anti-Sp4 and anti-CCAR1 autoantibodies in UK vs US patients with adult and juvenile-onset anti-TIF1γ-positive myositis

Lara D. Veeken(2024)10.1093/rheumatology/keae574

N/A

0DataRank · unranked

2 citations

Nophar Geifman, Hector Chinoy, Alexander Oldroyd, Janine A. Lamb, Lisa G. Rider +94 more